Telocytes promote hepatocellular carcinoma by activating the ERK signaling pathway and miR-942-3p/MMP9 axis

Ying Xu1, Hu Tian2✉, Chao Guang Luan3, Kai Sun2, Peng Jin Bao1, Hua Yu Zhang4 and Nan Zhang4

© The Author(s) 2021

In China, hepatocellular carcinoma (HCC) is considered a malignant tumor with a poor prognosis, frequent metastasis, and a high relapse rate. Telocytes (TCs) participate in tumorigenic, invasive, and migratory processes by secreting functional proteins and transmitting cell-to-cell information, but their functions in HCC are still unknown. TC counts and MMP9 expression in liver cancer tissues were measured using immunohistochemistry, western blotting, and RT-PCR. Primary TCs from liver para-cancer tissues were cultured in vitro. To verify the role of TCs in HCC, a metastatic cancer animal model was established using three types of liver cancer cell lines in vivo. TCs promoted HCC cell metastasis by MMP9 expression in vitro and in vivo. Platelet-derived growth factor-alpha (PDGF-α), secreted by HCC cells, activated the Ras/ERK signaling pathway in TCs, thereby increasing MMP9 expression; Moreover, miR-942-3p suppressed MMP9 expression in TCs. Our results reveal the role of TCs in HCC and the mechanisms by which they elicit their effects, and they may serve as novel prognostic markers for HCC.

Cell Death Discovery (2021) 7:209; https://doi.org/10.1038/s41420-021-00592-z

BACKGROUND

Globally, liver cancer is the sixth most common cancer and ranks fourth in terms of cancer-related mortality [1]. The World Health Organization estimates that more than 1 million patients will die of liver cancer by 2030 [2]. Metastasis, a common lethal feature in most malignant carcinomas, which involves secondary germination to distant organs, occurs through multiple steps, such as invasion of the circulatory system after tumor angiogenesis, sustainable growth with inexhaustible viability, and enhanced colonization capacity [3]. Cancer cells can overcome many obstacles by modifying the surrounding environment and regulating peripheral cells to establish appropriate conditions for metastasis. Although various efforts have been made to explore the molecular mechanisms involved in hepatocellular carcinoma (HCC), its prognosis is still made based on the clinical stage, distant metastatic organs, and postsurgical recurrence [4]. There is an urgent need for the discovery of novel biomarkers related to HCC metastasis and prognosis, and of new therapeutic targets.

Telocytes (TCs), derived from interstitial Cajal-like stem cells (ICLCs), are a novel type of mesenchymal cell with several long, thin, and bead-like telopodes (Tps), and are extensively exist in most mammalian organs [5–9]. TCs are positive for CD34, CD117, and PDGFR-α, and negative for CD28, vimentin, and nitric oxide synthase (NOS) in hepatic, renal, and vascular tissues [10]; these biomarkers are used for TC identification [11–13]. Studies on the role of TCs in tumorigenesis and cancer metastasis have been limited to their morphological and quantitative alterations in tumors. For instance, hyperplastic TCs were identified as the physiological counterparts of inflammatory fibroid polyp neoplasia and PDGFR-α mutant gastrointestinal stromal tumors [14]. Steroid hormone receptors on the membranes of TCs are involved in uterine leiomyoma growth by changing their density and local homeostasis [15]. Therefore, in this study, we sought to explore the potential mechanisms by which TCs influence tumor growth and cancer metastasis.

MMP9, one of the matrix metalloproteinases (MMPs) that participates in matrix remodeling of tissues [16, 17], and in cancer migration, invasion, and tumorigenesis [18, 19], can be secreted by ICLCs such as TCs through homocellular junctions to interact with surrounding cells. It has been reported that downregulating MMP9 expression suppresses HCC metastasis [20, 21]. Several signaling pathways such as the phosphoinositide 3-kinase/protein kinase B/nuclear factor-kappa B (PI3K/AKT/NF-kB) signaling pathway and the transforming growth factor-beta (TGF-β)/SMAD signaling pathway, control MMP9 expression [21–23]. Inhibition of the extracellular signal-regulated kinase (ERK) was found to reduce MMP9 expression, and gain-of-function was found to be reversed by eliminating mitogen-activated protein kinase (MAPK)-related inhibitors in fibrosarcoma [24]. In addition, iron mediates MMP9 expression through the ERK1/2 signaling pathway in head and neck squamous cell carcinomas [25]. The aim of our study was to elucidate the role played by TCs in HCC and the interactions...
between HCC cells and TCs, and to propose a possible mechanism for the role of TCs in HCC.

RESULTS

Diversity and correlation analyses between TCs and MMP9 in HCC

First, TCs cultured in vitro were authenticated through unique morphological features observed under the light microscopy (Fig. 1A, B) and through CD34+, PDGF-α, and CD117-positive immunofluorescence (IF) staining (Fig. 1D–F). The special features of TCs included several long and thin telopodes, which are characteristics that differentiate them from fibrocytes and epithelial cells (Fig. 1C) [26].

To verify changes in TC counts in HCC tissues, a double IF assay was carried out using 132 specimens to determine the number of CD34+ TCs in HCC and para-cancer tissues (Fig. 2A, panels a, e). TC counts in HCC tissues were significantly lower than those in para-cancer tissues as shown by the paired t-test (t value = 57.640, p < 0.0001, Fig. 2B). MMP9 expression indices in HCC tissues were lower than those in para-cancer tissues (t value = 138.600, p < 0.0001, Fig. 2A, B). The MMP2, MMP3, MMP9, MMP11, and MMP14 contents of both tissues were determined by western blot analysis, qRT-PCR analysis, and immunohistochemistry (IHC) staining (Fig. 2C, D, E). Expression levels of MMP2 and MMP14 were similar in both tissue types; MMP3 protein expression was lower in para-cancer tissues than in HCC tissues; MMP11 protein expression was higher in HCC tissues. In addition, the correlation between MMP9 expression and TC levels in both tissues was demonstrated through Pearson’s correlation statistical analysis (Table 1). To determine potential clinical correlations among MMP9 expression, TC counts, and HCC metastasis, we analyzed TC counts in tissues obtained from 93 metastasized HCC patients and 39 HCC patients without metastasis. TC counts and MMP9 expression in para-cancer tissues were significantly higher in samples of patients with metastasis than in those of patients without metastasis (Fig. 3A, B). To explore the potential function and significance of TCs in the HCC metastasis process, two hierarchical classifications were established based on TC counts, with low-count being ≤8/μm² and high-count being >8/μm². Patients in the high-TC group were younger than those in the low-TC group (65.510 ± 0.934 vs 75.763 ± 1.640 years, p = 0.001). The rate of metastasis was higher in the high-TC group than in the low-TC group (Table 2). Furthermore, MMP9 expression was higher in the high-TC group than in the low-TC group (7.859 ± 0.349 vs. 7.138 ± 0.273, p = 0.001). Overall survival (OS) in the high-TC group was significantly shorter than that in the low-TC group. In the same way, OS was shorter in patients with high MMP9 expression levels than in those with low MMP9 expression levels (high-MMP9 10.455 ± 3.290 vs. Low-MMP9 19.932 ± 2.028 months; Fig. 3C). A multivariate analysis that adjusted for age, sex, metastasis stage, MMP9 expression, and TC count revealed that MMP9 expression and TC count were independent hazard factors for HCC (Table 3).

Interactions between TCs and HCC cells

To investigate the role played by TCs in HCC, we chose three distinct cancer cell lines on which wound healing and Transwell assays were performed. Our findings indicated that TCs promoted the migration (Fig. 4A) and invasion (Fig. 4B) capacities of HepG2, SNU182, and SK-HEP-1 cells, and that inhibiting MMP9 expression attenuated TC function. We designed in vivo assays using xenograft mouse models by injecting HepG2 cells and TCs into mouse axillae (Fig. 4C). After 21 days, the weights and volumes of the HepG2 tumors following the fifth TC injection were significantly greater in the TC injection group than in the control and MMP9 inhibitor groups (p < 0.01; Fig. 4D). There was no significant difference in migration and tumor growth between the control group and the MMP9 inhibitor group (p > 0.05). The findings indicated that TC activity in HCC depended on MMP9. Within a certain range (from the first to the fifth TC injection), higher TC counts were associated with progressively larger tumor volumes (Fig. 4F). To confirm the molecular mechanisms underlying TC activity, we designed a lentivirus loaded with short hairpin RNA (shRNA) to knockdown MMP9 in TCs and PDGF-α in HCC cells, which could create loss-of-function cell-lines. The migration and invasive capacities of HepG2, SNU182, and SK-HEP-1 cells were retested through the wound healing (Fig. 4G, I) and transwell assays (Fig. 4H, J). Without MMP9, TCs lost the function of promoting cancer cell migration and invasion. We also used nude mice to establish lung metastatic liver cancer lesions and distinguished subgroups according to the different frequencies of
mouse tail vein TC injections (Fig. 4K). The extent of lung metastatic cancer lesions increased with increasing frequency of TC injection (Fig. 4K, panel a). IHC staining revealed that MMP9 expression levels were higher in the TC injection group than in the control group (Fig. 4K, panel b). The body weights of mice that received 2 TC injections in the TC injection group were lower than those of mice in the control group and mice that received only 1 TC injection (Fig. 4L). Lung tissue weight increased in the TC injection group as compared to the control group (Fig. 4K, panel c; 4 M).
Fig. 2 Differences in telocyte and MMP9 expression between the hepatocellular cancer (HCC) and para-cancer tissues. A CD34-positive telocytes (red) in the HCC and para-cancer tissue (a, e). MMP9 expression in both tissues as determined by immunohistochemistry and immunofluorescence (b, c, f, g). Distribution of telocytes (CD34+, green) and MMP9 (red) in the same paired tissue, and the relationship between them as determined by immunofluorescence (d, h). B Quantified telocyte count and MMP9 expression, and their statistical significance in 132 paired HCC and para-HCC tissue specimen (**p < 0.0001). C Some members of the MMP protein family, including MMP2, MMP3, MMP9, MMP11, and MMP14, expressed in 132 HCC tissues as compared to para-HCC tissues as determined by the western blot technique. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used to normalize the concentration. D qRT-PCR determination of the distinct expressions of MMP proteins in HCC tissues. E Different expressions levels of some MMP proteins in cancer and para-cancer tissues as determined by immunohistochemistry. The star symbol denotes statistical significance at p < 0.05. The scale bar denotes 50 μm in (A) and 100 μm in (E). Data are represented as mean ± SD, and the level of significance was determined using the paired t-test.

| Table 1. Pearson’s correlation of MMP-9 expression and telocyte number in HCC tissues. |
|-----------|
| MMP-9 expression | Correlation coefficient | Significance (p value) |
|------------|-----------------|------------------|
| MMP-9 expression | 0.898* | 0.011* |
| Telocyte number | 0.687** | 0.001** |

The analysis implies significant positive correlation between the two factors. The correlation between MMP-9 protein and telocytes is significant.

*The cancer tissues (p < 0.05).

bThe para-cancer tissues (p < 0.05).

Mechanism of TC MMP9 expression
To clarify the effects of PDGF-α on MMP9 expression in TCs, we first verified whether HCC cells secreted MMP9 using IHC staining, and found that HepG2 cells expressed PDGF-α but not MMP9 (Fig. 5A). MMP9 expression in TCs was determined using different doses of PDGF-α. It was found that 5 μl of PDGF-α acting on 6 x 10⁴ TCs resulted in maximum MMP9 secretion (Fig. 5B). Based on information obtained from the KEGG Database (https://www.genome.jp/kegg/), we found that PDGF-α stimulates TCs to secrete MMP9 by activating the MAPK signaling pathway. We constructed a simulated diagram of the ERK signaling pathway to demonstrate this molecular mechanism (Fig. 5C) [27]. Comparison with the negative control group revealed that PDGFR-α, functioning as a receptor on the membrane of TCs, transmitted an activation signal via Son Of Sevenless (SOS) and growth-factor-bound-2 (Grb2) to stimulate downstream effector proteins for the induction of Ras/ERK signaling. Grb2-sos compound activation, RAF activation, and MEK/ERK phosphorylation, as well as MMP9 expression, were detected by western blot (Fig. 5D). With the administration of the RAF inhibitor, AZ-628 [28], and the ERK inhibitor, U0126 [29], RAF activation, phosphorylation of MEK/ERK, and MMP9 expression were suppressed (Fig. 5D).

According to the miRBase and TargetScan databases, MMP9 is an accurate target of miR-942-3p. Through qRT-PCR analysis, miR-942-3p expression in TCs from HCC para-cancer tissues was found to be higher than that in TCs from normal liver tissue (Fig. 5E). Therefore, a luciferase reporter gene assay was performed, and it was observed that miR-942-3p-mimics significantly reduced MMP9 WT reporter luciferase activity, with no significant change observed in the MMP9 MUT group (Fig. 5F, G). Through qRT-PCR analysis and western blotting, over-expression of miR-942-3p was found to suppress MMP9 expression at both the mRNA and protein levels (p < 0.01, Fig. 5H–J).

DISCUSSION
In this study, multivariate analysis revealed that high TC density and MMP9 expression were correlated with poor OS. These results are consistent with those of previous studies which found an association between abnormal MMP9 expression and breast cancer tumor malignancy [22], lymphatic metastasis, and clinical stage [30], and a close relationship between MMP9 expression and poor primary HCC prognosis [31, 32]. By their basic functions, TCs mainly participate in changing microenvironmental metabolism [33]. Through Spearman’s statistical analysis, we found that MMP9 expression was positively correlated with TC count in HCC para-cancer tissues, and that TCs also secreted MMP9 in vivo. Therefore, we theorized that TCs might produce certain MMPs to regulate tumorogenesis. MMP9 has the capacity to degrade gelatin and type IV, V, and XI collagen, which form the barrier of the extracellular matrix (ECM) [33] and participate in cancer metastasis [34]. The role of TCs in HCC cell migration and invasion (HepG2, SNU182, and SK-HEP-1 cell lines) was identified in through the transwell and wound healing assays. We found that TCs lost their migration and invasion capacities in the presence of an MMP9 inhibitor in vitro and in vivo. These findings provide the first evidence of how TCs could promote HCC metastasis by producing and secreting MMP9.

HCC cells can secrete multiple chemokines, growth factors, and inflammatory cytokines, including the vascular endothelial growth factor and PDGF-α, to regulate surrounding cells and change the tumor microenvironment (TME). PDGF-α has been associated with lymphangiogenesis and angiogenesis in gliomas, sarcomas, leukemias, and epithelial cancers [35, 36]. PDGF-α and VEGF expression has been associated with poor prognosis in many malignant tumors [37, 38]. HCC cells secrete PDGF-α and VEGF to facilitate cell proliferation, migration, and invasion [39]. In this study, we found that the combination of PDGF-α with PDGFR-α, which is present on the surface of TCs, stimulates TCs to express MMP9. To illustrate the mechanisms involved in the MMP9 related signaling pathway, we used the Kyoto Encyclopedia of Genes and the Genomes database to search for feasible MMP9 signaling pathways. Through this search, we found that PDGF-α affects MMP9 expression via the ERK signaling pathway. Western blot analysis showed that PDGF-α activated Grb2-sos and Raf in TCs, and contributed to MEK1/2 and ERK1/2 phosphorylation, resulting in increasing MMP9 expression. This process could be inhibited using different Raf/ERK inhibitors such as AZ-628 and U0126 as a way to downregulate MMP9 synthesis. We concluded that through MMP9 expression, induced by PDGF-α, TCs promote HCC metastasis by activating the ERK signaling pathway. Therefore, TCs and HCC cells build a network, and TCs can be considered as counterparts of HCC cells as they facilitate cancer cell invasion and migration. Coincidently, TC hyperplasia, which is manifested by the submucosal thickening, characteristic of the PDGFR-α mutant syndrome, has been pathogenetically associated with inflammatory fibroid polyps and their physiological counterparts in the muscularis propria of gastrointestinal stromal tumors [14]. TCs appear to be crucial in regulating oncogenicity and the neoplastic circumjacent environment. In contrast, a decrease TC count also contributes to genuine fibrosis development in Crohn’s disease, ulcerative colitis, and liver fibrosis [40].

miRNAs are noncoding RNAs constituted of 18–25 nucleotides that degrade mRNA or inhibit translation by binding to the 3′UTR of their target RNAs [41]. Numerous miRNAs directly or indirectly regulate or control cell biological processes, including tumor
metastasis and cell division, proliferation, and death. For instance, miR-128-3p functions as a tumor suppressor and triggers cell cycle arrest by repressing LIMK1 expression in breast cancer [42]; downregulation of miR-34a reduces HCC metastasis [31]. Based on TargetScan Database predictions miRNAs associated with MMP9 mRNA in TCs include miR-942-3p, miR-6792, miR-34, and miR-6734. In this study, levels of miR-942-3p in TCs cultured from HCC para-cancer tissues were significantly lower than those in normal liver tissues. Through luciferase and western blot assays, by the decreased cell invasion, migration, and cancer metastasis observed, we demonstrated that miR-942-3p repressed MMP9 expression. Mimics of miR-942-3p significantly reduced MMP9 expression. Downregulation of mi-942-3p was found to be the mechanism of MMP9 toxicity and the springboard used by TCs to promote HCC metastasis.

Two molecular mechanisms underlying the interactions between HCC cells and TCs account for the regulation of MMP9 expression and the mechanism by which TCs accelerate cancer cell metastasis. Activation of the Raf/ERK signaling pathway and downregulation of miR942-3p play pivotal roles in enhancing MMP9 expression and promoting HCC metastasis, respectively. Although miR-942 has been reported to regulate various informational pathways and protein expression, whether it regulated the activation or inhibition of the ERK signaling pathway, or whether PDGF-α can suppress miR-942-3p expression synchronously requires further investigation.

Fig. 3 Comparison of telocyte count and MMP9 expression in HCC para-cancer tissues between the metastasis and non-metastasis groups. A Different MMP9 expression levels in the HCC tissues without metastasis (a) and with metastasis (b) as determined by immunohistochemistry staining. The relationship and distribution of telocytes (green) and MMP9 (red) in the para-cancer tissues are disparate between non-metastasis (c) and metastasis (d) samples as determined by immunofluorescence staining. B Telocytes counts and MMP9 expression in the metastasis (n = 93) and non-metastasis (n = 39) groups were statistically significantly different. C Kaplan–Meier analysis of overall survival (OS) in HCC patients (n = 265) with low (red line) or high (blue line) telocyte counts (left panel) and low (red line) or high (blue line) MMP9 levels (right panel) (p < 0.05, Log-rank test). ****p < 0.001, ****p = 0.001.
Clinical samples

Between January 2018 and June 2020, surgical tissues were collected at the first affiliated hospital of Shandong first Medical University from 132 patients with HCC confirmed by fast pathology biopsy during the operation, after signed informed consent was obtained from the patients. All fresh tissues were immediately stored in a refrigerator at −80°C and anonymized before transfer to the laboratory for further processing. Patient demographic data, including age, sex, clinical classification, survival time, and relative follow-up visits were collected. All control subjects, who were free of liver malignancy, were followed up for two and a half years.

MATERIALS AND METHODS

Clinical samples

Between January 2018 and June 2020, surgical tissues were collected at the first affiliated hospital of Shandong first Medical University from 132 patients with HCC confirmed by fast pathology biopsy during the operation, after signed informed consent was obtained from the patients. All fresh tissues were immediately stored in a refrigerator at −80°C and anonymized before transfer to the laboratory for further processing. Patient demographic data, including age, sex, clinical classification, survival time, and relative follow-up visits were collected. All control subjects, who were free of liver malignancy, were followed up for two and a half years.

Primary TC culture

Fresh liver para-cancer and hepatic hemangioma (as the control group) tissues, obtained after surgery, were cut into smaller pieces, and incubated with 5 mg/ml collagenase type II (Sigma-Aldrich, St. Louis, MO, USA) for 10 min. Then, samples were washed twice with calcium- and magnesium-free PBS (pH 7.4, G0002, Servicebio, USA) and centrifugated at 10000 r.p.m. for 5 min, and then resuspended in DMEM (Gibco-8120217, NY, USA) supplemented with 10% fetal calf serum. The BJ-40 capillary glass tube (1.0 mm outer diameter, 0.8 mm inner diameter; Hengtong Technology Company, Beijing, China) was soaked in 1 mol/L hydrochloric acid for 24 h, rinsed continuously with ultrapure water, dried at 65°C, and autoclaved. Under x200 magnification of the microscope and selected cells to 0.2 mL centrifuge tubes containing 2 μL of lysate according to the morphology of TCs [43, 44].

Lentivirus production and transfection

To obtain stable experimental cell lines, primary TCs from mouse hepatic tissues were transfected with SV40 large and small T antigens to obtain TC- SV40. TC-SV40 cells were cultured in Dulbecco’s modified Eagle’s medium/F12 supplemented with 10% fetal calf serum (Gibco-8120330, NY, USA). HepG2, SNU182, and SK-Hep1 cell-Lines were cultured in DMEM (GIBCO, Beijing, China) supplemented with 10% FBS, 100 U/ml of penicillin, and 100 μg/ml streptomycin. These cells were incubated at 37°C in a humidified atmosphere containing 5% CO2. When cells reached 60–80% confluence, positive and stable transfectants were selected for the subsequent experiments.

RNA extraction and qRT-PCR analysis

To determine MMP2, MMP3, MMP9, MMP11, and MMP14 mRNA expression levels in HCC and para-cancer tissues, qRT-PCR analysis was performed. Total RNA was extracted from tissues using the Trizol reagent (CW0581, Kangweiishiji company, China) according to the manufacturer’s protocol [46]. Reverse transcription and cDNA amplification were performed using the SYBR master mix (CW0957, Kangweishiji company, China) according to the manufacturer’s guidelines. B-actin genes were used as internal controls. The primary sequences were shown in Supplementary Table 1. The computational format of mRNA expression = 2−△△CT.

RNA interference

For the miR-942-3p test, complete miRNA sequences were obtained from the miBase database; shRNAs and mimics of the indicated miRNA were purchased from RiboBio Company (Shanghai and Wuhan, China). Transfection with shRNAs and miRNAs was performed using niboFECT™ CP (RiboBio, Wuhan, China) according to the manufacturer’s instructions. The statistical had significant when p < 0.05.

Table 2. Comparison between low and high telocyte groups of HCC patients.

|                | Low-telocyte (n = 38) | High-telocyte (n = 94) | t/p value |
|----------------|-----------------------|------------------------|-----------|
| Age, mean ± SD, years | 75.763 ± 1.640         | 65.510 ± 0.934         | 45.25/0.001 |
| Sex, male/female | 16/22                 | 55/39                  |           |
| Metastasis, number (%) | 12 (31.6)              | 82 (87.2)              |           |
| M1             | 26 (68.4)             | 12 (12.7)              |           |
| MMP9, mean ± SD, μm²/mg/mm³ | 7.138 ± 0.273         | 7.859 ± 0.349         | 13.66/0.001 |
| OS, mean ± SD, months | 17.234 ± 3.290         | 9.263 ± 2.606         | 13.33/0.000 |

MMP9 matrix metalloproteinase-9. The statistic had significant when p < 0.05, MMP9.

Table 3. Multivariate analysis of overall survival in HCC patients.

|                | HR      | 95% CI | Multivariate P-value |
|----------------|---------|--------|-----------------------|
| Age            | 0.633   | 0.453–0.905 | 0.077               |
| Sex            | 0.759   | 0.536–1.032 | 0.106               |
| Metastasis     | 0.402   | 0.270–0.577 | 0.000               |
| MMP9 (para-cancer tissue) | 0.572 | 0.480–0.993 | 0.001               |
| TCs (para-cancer tissue) | 0.698 | 0.412–0.891 | 0.001               |

MMP9 Matrix metalloproteinase-9, TCs Telocytes, HR hazard ratio, CI confidence interval, HCC hepatocellular carcinoma. The statistic had significant when p < 0.05.

CONCLUSION

We demonstrated differences in TC and MMP9 expression in HCC tissues. We also described 2 potential mechanisms by which TCs promote HCC cell metastasis and stimulate MMP9 expression in vitro and in vivo. In addition, we found that PDGF-α, produced by HCC cells, activates the ERK signaling pathway in TCs to stimulate MMP9 expression, and that miR-942-3p suppresses MMP9 expression.

Western blot analysis

For western blot analysis, samples were thawed and resuspended using a lysis buffer (20% Glycerol, 4% SDS in 100 mM Tris Buffer, pH 6.8). Cell extracts were boiled for 10 min in loading buffer and then centrifuged at 12000 rpm for 10 min at 4°C using a microcentrifuge. The immune-reactive bands were colored using an ECL-PLUS/TM (Amersham company, UK). The antibodies are listed in Supplementary Table 2.

Lentivirus production and transfection

To reconstitute lentiviruses, 293T cells were co-transfected with plasmids of packaging, envelope, and expression. The virus-containing supernatant was collected and concentrated by ultra-centrifugation. The viral stock was supplemented with 8 mg/mL polybrene for infection.

Cell transfection

To obtain stable experimental cell lines, primary TCs from mouse hepatic tissues were transfected with SV40 large and small T antigens to obtain TC-SV40. TC-SV40 cells were cultured in Dulbecco’s modified Eagle’s medium/F12 supplemented with 10% fetal calf serum (Gibco-8120330, NY, USA). HepG2, SNU182, and SK-Hep1 cell-Lines were cultured in DMEM (GIBCO, Beijing, China) supplemented with 10% FBS, 100 U/ml of penicillin, and 100 μg/ml streptomycin. These cells were incubated at 37°C in a humidified atmosphere containing 5% CO2. When cells reached 60–80% confluence, positive and stable transfectants were selected for the subsequent experiments.

RNA extraction and qRT-PCR analysis

To determine MMP2, MMP3, MMP9, MMP11, and MMP14 mRNA expression levels in HCC and para-cancer tissues, qRT-PCR analysis was performed. Total RNA was extracted from tissues using the Trizol reagent (CW0581, Kangweiishiji company, China) according to the manufacturer’s protocol [46]. Reverse transcription and cDNA amplification were performed using the SYBR master mix (CW0957, Kangweiishiji company, China) according to the manufacturer’s guidelines. B-actin genes were used as internal controls. The primary sequences were shown in Supplementary Table 1. The computational format of mRNA expression = 2−△△CT.
Telocytes promote cancer cell metastasis depending on MMP9 expression. TCs promoted the migration of hepatic cancer cells as determined by the wound healing assay (A) and facilitated the invasion of hepatic cancer cells as determined by the Transwell assay (B). Representative photos of xenograft tumors in vivo, (C) growth curves of tumor weight (D) and volume (E) over time in the HepG2, TCs, and TCs + MMP9 inhibitor groups. Growth curves of tumor volume with incremental TC injections (F). Knockdown of MMP9 and PDGF-α in TCs and HCC, respectively, influenced the migration and invasion of hepatic cancer cells after 48 h as determined by the wound healing and Transwell assays (G, H). The number of migrating cells (I) and invasive cells (J) in the shMMP9 and shPDGF-α groups were determined. Representative photographs of metastatic lung tissues derived from HepG2 cancer cells at different frequencies of TC injections as determined by hematoxylin and eosin staining (K-a) and in vivo (K-c). MMP9 expression as determined by immunohistochemistry staining in the different groups (K-b). Contrast curves of the weights of nude mice (L) and the weights of metastatic lung tissues (M) at different frequencies of TC injection. ns: no significance; *p < 0.05, **p < 0.01, ***p < 0.005.
Immunohistochemistry (IHC) staining

Formalin-fixed paraffin-embedded primary tumor and para-cancer tissues were used for IHC analysis. For heat-induced antigen retrieval, slides were soaked in a citric acid buffer and maintained at a sub-boiling temperature for 8 min. Sections were observed using a light microscope (XSP-C204, CIC, China), and were scanned using a laser scanning confocal microscope (Eclipse Ti-E, Nikon, Japan) at a ×40 magnification. Datums were quantified in IHC digital slides using a Leica Aperio positive pixel count algorithm through whole slide analysis (PANNORAMIC DESK/MIDI/250/1000, 3DHISTECH, Hungary). Antibodies are shown in Supplementary Table 2.
Immunofluorescence (IF) staining
All sections were incubated twice in xylene for 15 min. The sections were dehydrated in two changes of pure ethanol using a dehydrator and were immersed in an EDTA antigen retrieval buffer (pH 8.0, G1206/G1203, Servicebio, USA). After the antibody reaction, photos were taken using a fluorescence microscope (TE-2000E, NIKON, Tokyo, Japan) with an imaging system (NIKON DS-U3, Tokyo, Japan). Images were captured at a magnification of 1–400 (Microscope Camera XSP-C204, Olympus Europa GmbH, Hamburg, Germany). Antibodies are listed in Supplementary Table 2.

Transwell assay
For the invasion assays, transwell migration chambers and Matrigel-coated chambers (Becton Dickinson, Waltham, MA) were used. In summary, 5 × 10^4 HCC cells were seeded into the upper chamber in a serum-free culture medium. The lower chamber was filled with 5 × 10^4 TCs in DME medium (Thermo Fisher, HyClone, UT, USA) with 10% FBS (Thermo Fisher Scientific, MA, USA). After 48 h of incubation, cells that crossed the membrane were stained with 1% crystal violet and quantified (maximum axis × minimum axis^2 ÷ 2). Each chamber was incubated at 37 °C in a 5% CO2 atmosphere for 48 h. The area was estimated using the Image J software.

Wound healing assay
Using a ball marker, horizontal lines were uniformly drawn on the back of a six-well plate. Approximately 2.5 × 10^5 HCC cells were added to the wells and incubated overnight to reach a fusion rate of 100%. A TC^340 supernatant was prepared after 24 h of culturing and added to the chambers of the plate. MMP9 inhibitor group was a concentration of 3 μM, adding each group of co-culture chambers into the corresponding wells. Each chamber was incubated at 37 °C in a 5% CO2 atmosphere for 48 h. In order to gain significant results, the number of animals in different groups should keep at least 5, and the dead mice were excluded from the experiment. Statistical analyses
SPSS version 20.0 (SPSS Inc., Chicago, IL, USA) was used for the statistical analyses. Quantitative variables were represented as the mean ± standard deviation (SD). Two-tailed Student’s t-tests, paired t-tests, chi-square tests, and multivariate analyses were used to evaluate the differences between groups. Pearson correlation analysis was used to determine the relationship between MMP9 expression and TC number in HCC tissues. Survival curves were constructed through Kaplan–Meier analyses, and values of P<0.05 were considered statistically significant.

REFERENCES
1. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7:6.
2. Lordick F. Hepatocellular carcinoma–united forces against a global killer. Ann Oncol. 2020;31:449–50.
3. Ko KL, Mak LY, Cheung KS, Yuen MF. Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Res. 2020;9:F100Faculty Res-620.
4. Piñero F, Dirschwolf M, Pessóa MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment. Cells 2020;9:1370.
5. Veress B, Ohlsson B. Spatial relationship between telocytes, interstitial cells of Cajal and the enteric nervous system in the human ileum and colon. J Cell Mol Med. 2020;24:3399–406.
6. Popescu LM, Manole CG, Gherghiceanu M, Ardelean A, Nicolae MS, Hinescu ME, et al. Telocytes in human epicardium. J Cell Mol Med. 2010;14:2085–93.
7. Suciu L, Popescu LM, Gherghiceanu M, Regalia T, Nicolae MS, Hinescu ME, et al. Telocytes in human tumor placenta: morphology and phenotype. Cells Tissues Organs. 2010;192:2325–39.
8. Hinescu ME, Gherghiceanu M, Suciu L, Popescu LM. Telocytes in pleura: two- and three-dimensional imaging by transmission electron microscopy. Cell Tissue Res. 2010;343:985–97.
9. Chen X, Zheng Y, Manole CG, Wang X, Wang Q. Telocytes in human oesophagus. J Cell Mol Med. 2013;17:1506–12.
10. Xu Y, Tian H, Qiao G, Zheng W. Telocytes in the atherosclerotic carotid artery: immunofluorescence and TEM evidence. Acta Histochim. 2021;123:151681.
11. Vannuchi MG. The telocytes: ten years after their introduction in the scientific literature. An update on their morphology, distribution, and potential roles in the gut. J Mol Med. 2020;41:4748.
12. Wang L, Xiao L, Zhang R, Jin H, Shi H. Ultrastructural and immunohistochemical characteristics of telocytes in human scalp tissue. Sci Rep. 2020;10:1693.
13. Rosa I, Marinii M, Sgambati E, Ibba-Manneschi L, Manetti M. Telocytes and lymphatic endothelial cells: two immunophenotypically distinct and spatially close cell entities. Acta Histochim. 2020;122:15130.
14. Ricci R, Guiditini MC, Gesi E, Lanza P, Casti F, Bianoli A, et al. Telocytes are the physiological counterpart of inflammatory fibroid polyps and PDGF-αA-mutant GISTs. J Cell Mol Med. 2018;22:4856–62.
15. Aleksandrovych V, Gil A, Wrona A. Sex steroid hormone receptors of telocytes - potential key role in leiomyoma development. Folia Med Cracov. 2020;60:81–95.
16. Cohen L, Sagl I, Bigelman E, Solomonov I, Alishon A, Ben-Shoshan J, et al. Correlation of cardiac remodeling secondary to chronic volume overload is attenuated by a novel MMP9/2 blocking antibody. PLoS ONE. 2015;10:e0241419.
17. Sapa-Wojciechowska A, Rak-Pasikowska A, Porma J, Czapla B, Bil-Lulu I. Extracellular matrix remodeling factors as markers of carotid artery atherosclerosis. Cardiol Res Pr. 2020;2020:9036157.
18. Joseph C, Alsaleem M, Orah N, Narasimha PL, Miligy IM, Kurozumi S, et al. Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Res Treat. 2020;182:267–82.
19. Liang Y, Lv Z, Huang G, Qin J, Li H, Nong F, et al. Prognostic significance of abnormal matrix collagen remodeling in colorectal cancer based on histologic and bioinformatics analysis. Oncol Rep. 2020;44:1671–85.
20. Scheau C, Badarau IA, Costache R, Caruntu C, Mihai GL, Didilescu AC, et al. Telocytes in human term placenta: morphology and phenotype. Cells Tissues Organs. 2010;192:325–39.
21. Wen Y, Cai X, Chen S, Fu W, Chai D, Zhang H, et al. 7-Methoxy-1-tetralone induces apoptosis, suppresses cell proliferation and migration in hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7:6.
22. Dong H, Diao H, Zhao Y, Xu H, Pei S, Gao J, et al. Overexpression of matrix metalloproteinase-9 in breast cancer cell lines remarkably increases the cell malignancy largely via activation of transforming growth factor beta/SMAD signalling. Cell Prolif. 2019;52:e12633.
23. Xuan L, Han F, Gong L, Lv Y, Wan Z, Liu H, et al. Ceramide induces MMP-9 expression through JAK2/STAT3 pathway in airway epithelium. Lipids Health Dis. 2020;19:196.
24. Marchese V, Juarez J, Patel P, Hutter-Lobo D. Density-dependent ERK MAPK expression regulates MMP-9 and influences growth. Mol Cell Biochem. 2019;456:115–22.
25. Kaomongkolpit R, Cheesupthorn P, Pavisant P, Sanchavanakit N. Iron increases MMP-9 expression through activation of AP-1 via ERK/Akt pathway in human head and neck squamous carcinoma cells. Oral Oncol. 2008;44:587–94.
26. Xu Y, Tian H, Cheng J, Liang S, Li T, Liu J. Immunohistochemical biomarkers and distribution of telocytes in Apoe−/− mice. Cell Biol Int. 2019;43:1286–95.
27. Marchese V, Juarez J, Patel P, Hutter-Lobo D. Density-dependent ERK MAPK expression regulates MMP-9 and influences growth. Mol Cell Biochem. 2019;456:115–22.
28. McDermott U, Sharma SV, Dowell L, Grencher P, Montagut C, Lamb J, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA. 2007;104:19936–41.
29. Duan W, Chan JH, Wong CH, Leung BP, Wong WS. Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model. J Immunol. 2004;172:7053–9.
30. Li H, Qiu Z, Li F, Wang C. The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis. Oncol Lett. 2017;14:5865–70.
31. Cao S, Zhu S, Yin W, Xu H, Wu J, Wang Q. Relevance of EGFR between serum VEGF and MMP-9 in primary hepatocellular carcinoma patients with transarterial chemoembolization. Onco Targets Ther. 2020;13:9407–17.
32. Cretoiu D, Cretoiu SM, Simionescu AA, Popescu LM. Telocytes, a distinct type of cell among the stromal cells present in the lamina propria of jejunum. Histol Histopathol. 2012;27:1067–78.
33. Bronisz E, Kurkowski-Jantrzewska I. Matrix metalloproteinase 9 in epilepsy: the role of neuroinflammation in seizure development. Mediators Inflamm. 2016;2016:7369020.
34. Mondal S, Adhikari N, Banerjee S, Amin SA, Jha T. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview. Eur J Med Chem. 2020;194:112260.
35. Senga SS, Grose RP. Hallmarks of cancer—the new testament. Open Biol. 2021;11:200358.
36. Yuge R, Kitadai Y, Shinagawa K, Onoyama M, Tanaka S, Yasui W, et al. mTOR and CDK4/6 are predictive markers for the efficacy of targeted therapy in hepatocellular carcinoma. J Hepatol. 2021;64:153–62.
37. Kaomongkolpit R, Cheepsunthorn P, Pavasant P, Sanchavanakit N. Iron increases MMP-9 expression through activation of AP-1 via ERK/Akt pathway in human head and neck squamous carcinoma cells. Oral Oncol. 2008;44:587–94.
38. Mohamed SY, Mohammed HL, Ibrahim HM, Mohamed EM, Salah M. Role of VEGF, CD105, and CD31 in the prognosis of colorectal cancer cases. J Gastrointest Cancer. 2019;50:23–34.
39. Chen B, Liu J, Wang X, Shen Q, Li C, Dai C. Co-expression of PDGF-α and VEGFR-3 strongly correlates with poor prognosis in hepatocellular carcinoma patients after hepatectomy. Clin Res Hepatol Gastroenterol. 2018;42:126–33.
40. Ibbba-Mannenche L, Rosa I, Manetti M. Telocytes in chronic inflammatory and fibrotic diseases. Adv Exp Med Biol. 2016;913:51–76.
41. Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer. 2021;21:22–36.
42. Zhao J, Li D, Fang L. Mif-128-3p suppresses breast cancer cellular progression via targeting LIMK1. Biomed Pharmacother. 2019;115:108947.
43. Sanches BDA, Maldarine JDS, Tamarindo GH, Da Silva ADT, Lima ML, Rahal P, et al. Explant culture: a relevant tool for the study of telocytes. Cell Biol Int. 2020;44:23495–408.
44. Romano E, Rosa I, Fioretto BS, Lucattelli E, Innocenti M, Ibbba-Mannenche L, et al. A two-step immunomagnetic microbead-based method for the isolation of human primary skin telocytes/CD34+ stromal cells. Int J Mol Sci. 2020;21:5877.
45. Lis GJ, Dubrowski A, Lis M, Soleswki B, Witkowska K, Aleksandrovych V, et al. Identification of CD34+ /PDGFRα+ valve interstitial cells (VICs) in human aortic valves: association of their abundance, morphology and spatial organization with early calcific remodeling. Int J Mol Sci. 2020;21:6330.
46. Lucchetti C, Genchi M, Venco L, Bazzocchi C, Kramer LH, Vismarra A. Optimized protocol for DNA/RNA co-extraction from adults of Dirofilaria immitis. MethodsX 2019;6:2601–5.

ACKNOWLEDGEMENTS
We thank all scientists in the Medical Research Center of Shandong Provincial Qianfoshan Hospital. Natural Science Foundation of Shandong Province(ZR2019MH116)

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS APPROVAL
The study was assessed and approved by the Institutional ethic committee of The First Affiliated Hospital of Shandong First Medical University. All subjects about patients were all consented.

CONSENT FOR PUBLICATION
All authors agree to publish this article.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41420-021-00592-z.
Correspondence and requests for materials should be addressed to H.T.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021